Choroideremia (CHM) is an X-linked recessive eye disease that results from mutations involving the Rab escort protein-1 (REP-1) gene. In 18 patients deletions of different sizes have been found. Two females suffering from CHM were reported to have translocations that disrupt the REP-1 gene. In 22 patients, small mutations have been identified* Interestingly, these are all nonsense, frameshift or splice-site mutations; with one possible exception, missense mutations have not been found. This comprises all the known mutations in the disease. Hum Mutat 9:110-117, 1997. © 1997 Wiley-Uss, Inc. key w o r d s : c h o r o i d e r e m i a (CHM), m u t a t i o n s , r a b e s c o r t p r o t e i n -1 (REP-1)
gene by X-autosomal translocations (Kaplan et ab, 1989; Siu et al., 1990) . In these cases, X-inactivation is nonrandom; the normal X is preferen tially inactivated, while both translocation frag ments remain active.
The gene for CHM was localized to the X q l3 -q22 region by linkage analysis (Lewis et a l., 1985; Nussbaum et alM 1985; Lesko et al., 1987; Sankila et al., 1989) . This assignment was further refined by the characterization of cytogenetically visible deletions in patients with CHM, mental retardation(M R), and deafness type 3 (DFN3) (Rosenberg et al.} 1987; Schwartz et al., 1988; Cremers et alM 1989a) . Molecular analysis of deletions in patients with classic CHM (Cremers et al., 1987 (Cremers et al., , 1989b (Cremers et al., , 1990a formed the basis for the positional cloning of a part of the CHM gene from Xq21.2 (Cremers INTRODUCTION Choroideremia (CHM) is an X-linked recessive eye disorder characterized by progressive degener ation of the choroid, retinal pigment epithelium (RPE), and retina (Goedbloed, 1942; Waardenburg, 1942) . Its incidence is estimated as 1 in 100,000. T he clinical manifestation of CHM shows considerable interfamilial as well as intrafamilial variability. Usually, affected males develop night-blindness in their teenage years, followed by progressive constriction of visual fields and com plete blindness by middle age. Female carriers gen erally show no serious visual impairment, but they have patchy pigmentation and degeneration of the RPE suggesting clonal areas o f disease attributable to random X-inactivation (Heckenlively and Bird, 1988) . Occasionally, female carriers show clinical signs of CHM that can be ascribed to skewed X-inactivation (Fraser and Friedmann, 1968; Harris and Miller, 1968 Insight into the function of the CHM protein came with the biochemical purification of Rab geranylgeranyl transferase (Rab GGTase) from rat brain. This multisubunit enzyme attaches geranylgeranyl (GG) groups to Rab proteins, a modi fication essential for their action in intracellular vesicular transport, Rab GGTase consists of a cat alytic a /p heterodimer and an accessory compo nent, the Rab escort protein (REP). Molecular cloning of rat REP-1 revealed identity with the protein encoded by the CHM gene (Seabra et al., 1992a (Seabra et al., ,b, 1993 ; Andres e ta l., 1993). REP-1 binds to newly synthesized Rab proteins, presents them to the catalytic part of the enzyme, and delivers the prenylated Rabs to their target membranes (Andres et a l., 1993; Alexandrov et al., 1994) .
In yeast, both the a/(S catalytic component of Rab GGTase (encoded by the BET4 and BET2 genes) and REP (encoded by the MRS6/MSI4 gene) are essential for cell viability (W aldherretal., 1993; Jiang et al., 1993 Jiang et al., , 1994 ; Benito-Moreno et a l, 1994; Fujimura et al., 1994; R agninietaL , 1994) . A complete loss of REP activity would likely be lethal in humans too. Lymphoblasts of CHM pa tients have a markedly decreased but still detectable Rab GGTase activity , sug gesting that there is compensation for the defi ciency of REP-1. Indeed, an autosomal homologue of the REP-1 gene has been identified that was designated CHML for choroideremia-like. The gene is located in lq42-qter and, like the REP-I gene, is expressed in a wide variety of tissues (Crem ersetal., 1992; van Bokhoven eta l., 1994c). The CHML protein, or REP-2, was demonstrated to perform a function similar to that of REP-1. It was therefore hypothesized that REP-2 substitutes for the loss of REP-1 activity in choroideremia pa tients, thereby preventing symptoms in tissues and organs other than the eye (Cremers et al., 1994)* The apparent insufficient com pensation in the eye might be due to the presence o f a Rab or Rabs that depend preferentially on REP-1 for geranylgeranylation. Recently, Seabra et al. (1995) identified an unprenylated Rab protein in lymphoblasts from CHM patients that was prenylated more efficiently by REP-1 than by REP-2. This protein, Ram/ Rab27, is also present at high levels in the RPE and choriocapillaris, suggesting that CH M may result from the deficient geranylgeranylation o f Ram/ Rab27 or a closely related protein.
HEP-1 GENE DEFECTS D eletions
About one-fourth of European patients with classic choroideremia have large deletions that in volve the REP-J g en e.1 By contrast, no deletions have been found in the N orth Am erican popula tion yet (Merry et a l., 1992). T he size of the de letions varies widely and ranges from a few kilobases removing a single exon, to 5 -1 5 Mb spanning the complete REP-1 gene (Fig. 1) . Only 3 out of 18 deletions are located entirely within the REP-1 gene, while the others have at least one endpoint outside the gene. D eletion breakpoints show a random distribution except for 5 deletions that all end distally between exon 1 and p]7.6B. These clustered endpoints have not been charac terized in detail and the physical size of the chro mosomal segment betw een exon 1 and pJ7«6B is not known. Apart from this region there are no obvious hotspots for the induction of chromosomal breakpoints near or w ithin the REP-1 gene. 1This is based on the preliminary outcome of REP-1 mutation screening in a large group of unrelated CHM patients. In 39 of these patients, the entire REP-1 protein coding has been screened: 10 patients have deletions, 16 patients have subtle mutations, and in the remaining 13 patients no mutations have been identified. gene to date are listed in Table 1 . These mutations were identified by single strand conformation anal yses and heteroduplex analyses of the protein cod ing region of the REP-J gene* CN, TN, FC, and JW are numbered 2, 3, 4, and 5 , respectively, in the study by Schwartz et al. (1993) . cSee text.
Translocations X-autosome translocations that involve the REP-1 gene have been reported in two females

Nonsense Mutations and Frameshift Mutations
So far, seven nonsense mutations have been de tected in the REP-1 gene. In addition, seven dif ferent deletions and insertions were identified that result in translational frameshifts and premature termination codons (Table 1) . One frameshift mu tation, a deletion of the tetranucleotide TGTT in exon 13, was found in three apparently unrelated patients from Germany, France, and Denmark. It is of note that in the normal REP-1 gene the TG TT tetranucleotide is duplicated, which may render this sequence particularly susceptible to mu tation (e.g., by polymerase slippage during repli cation).
Splice Site Mutations
Included in Table 1 are six mutations that affect splice sites. Patient P21.420 has a 3-bp insertion at the 5' splice site Ln intron 10, Reverse transcriptase PCR (RT-PCR) analysis (Fig. 2: primers 5 and 6) showed that in about 80% of the patient's REP-1 mRNA exon 10 is absent, while the remaining 20% lacks exons 10 and 11. Skipping of exon 10 main tains the reading frame* but deletion of exons 10 and 11 causes a frameshift resulting in a premature In family M, an A -*T change at position 1442 in exon 11 predicts the substitution of a leucine for a glutamine and was therefore reported as a possi bly causative missense mutation (Donnelly et alM 1994). However, this nucleotide alteration also af fects the 5' splice junction in exon 11. The simi larity to the consensus sequence is reduced from 86% for the authentic splice site (AG/gtaaat) to 78% for the mutated splice site (TG/gtaaat) (ac cording to Shapiro and Senepathy, 1987) . Whether this actually results in splicing artifacts has not been studied.
Van Bokhoven et al. (1994a) reported another potential splice acceptor mutation, a T">G change at position -14 in intron 4, in patient PU. How ever, RT-PCR analysis (Fig. 2: primers C and D) showed that this substitution does not affect REP-1 RNA processing (M. Schwartz, unpublished obser vations). Table 2 lists the known polymorphisms in the REP-1 gene. The two intragenic highly polymor phic microsatellite markers have a combined het erozygosity index of 0.96.
POLYMORPHISMS
DISCUSSION
The deletions that are shown schematically in Figure 1 are all expected to result in an absent or a nonfunctional REP-1 gene product. Not surpris ingly there is no obvious conelation between the size or the breakpoints of the deletions and the clinical manifestation of choroideremia in these patients.
The two female patients carrying balanced X-autosome translocations that involve the REP-1 gene (Fig. 1) show a mild disease course. Usually, in females with reciprocal X-autosomal translocations the normal X is preferentially inactivated while both translocation fragments remain active. How ever, there is evidence that the REP-1 gene partly escapes X-chromosome inactivation (Carrel and  Willard, 1993; T.J.R.v.d. Pol and J.A.J.M.v.d.  Hurk, unpublished observations) . The presence of a low level of functional REP-1 transcript could account for the mild manifestation of choroideremia in these female patients.
Point mutations and small insertions/deletions have been found in exons 5 -1 4 of the REP-l gene (Table 1) . Recombinant REP-1 protein that lacks the 49 C-terminal amino acids is still able to assist in the geranylgeranylation of Rab proteins (F.P.M. Cremers and M. Seabra, unpublished observa tions), indicating that mutations in exon 15 may not cause CHM. The reason for the absence of subtle mutations in exons 1-4 is unclear.
The majority (70%) of small alterations in the REP-1 gene are nonsense and frameshift mutations that result in premature translation termination codons (Table 1) . In many instances, the primary consequence of a premature stop codon is severe or complete loss of mRNA from the mutant allele. A normal level may be retained if the inappropriate termination codon occurs toward the 3 ' end of the transcript (McIntosh et al., 1993) . If any protein is produced from the mutant allele it will be trun cated at the C-terminus. Recently, it has been shown that recombinant REP-1 protein that lacks the 70 C-terminal amino acids is unable to func tion as a subunit of Rab GGTase (F.P.M. Cremers and M. Seabra, unpublished observations). Since the aforementioned nonsense and frameshift mu tations in the REP-1 gene predict C-terminal trun cations of more than 70 amino acids, it is clear that any resulting REP-1 proteins will be nonfunc tional.
The remaining 30% of small alterations in the REP-1 gene are mutations that affect splice sites (Table 1 ). In family M, the A->T change at po sition 1442 not only alters the 5' splice site in exon 11 but also predicts a glutamine to leucine substi tution. The effect of the point mutation has not been determined directly, yet Western blot analy sis failed to detect any REP-1 protein in EBV trans formed lymphoblasts of a patient from this family (M. Seabra and O. Pascal, personal communication). Although it cannot be excluded that an amino acid substitution generates a highly unstable protein, it is more likely that the A -»T change affects RN A splicing or, since only one third of the coding region was screened, that there is another mutation in the REP-1 gene in this family. Further studies are required to establish the status and ef fect of the A-»T change. Three splice site muta tions listed in Table 1 have The (vast majority of) subtle mutations ap p eals) to completely inactivate the REP-1 gene product. This finding explains why there is no ap parent correlation between the clinical severity of the disorder and the underlying mutations. The striking absence of missense mutations may indi cate that these have no clinical effect. However, this would imply a low pressure on sequence con servation, which is contradicted by the high degree of homology between the human, rat, and mouse sequences, and by the fact that only one polymor phism was ever found in the protein coding region of the human REP-1 gene. A more likely possibil ity would be that missense mutations give rise to a different disease phenotype. Alternatively, they may be lethal because of interference with the function of the REP-2 gene product; for example, the resulting REP-1 proteins may be able to irre versibly bind the a/p catalytic component of Rab GGTase.
The spectrum of REP-1 gene defects described here enables the definition of the most efficient strategy for future mutation screening. So far, de tection of REP-1 mutations has largely been per formed on genomic DNA, In view of the frequent occurrence of gross rearrangements, a preliminary screen for (partial) REP-1 deletions by polymerase chain reaction (PCR) amplification of exons 1, 8, and 15 would be a logical first step in mutation detection. Subsequently, all exons and adjacent intronic sequences could be PCR-ampIified from genomic DNA and scanned for small alterations using single-strand conformation analysis (Orita et al,, 1989) , 1993) . Alternatively, mutation analysis could be carried out on mRNA derived from lympho blasts. This might be a more practical starting ma terial since larger stretches of coding sequences can be screened, and the effect of the mutation on transcript structure can be readily observed. The first step in mRNA analysis, RT-PCR (Fig. 2) , detects gross rearrangements and mutations that affect splicing. More subtle mutations in the RT-PCR products can be detected by chemical mis match cleavage (Cotton et al., 1988) or protein truncation tests (PTT) (Roest et ah, 1993) . The latter method specifically detects translation ter mination mutations. Since virtually all nondele tion CHM cases analyzed so far are small mutations that introduce premature termination codons, PTT might be the method of choice for REP-1 mutation screening.
In approximately one-third of European CHM patients screened for defects in the REP-1 protein coding region, the causative mutation has not 116 VAN DEN HURK ET AL* been identified. It should he .stressed that this is generally not a problem for genetic counseling be cause in most (familial) cases intragenic polymor phisms (Table 2) , in particular the two highly polymorphic microsatellites, enable accurate presymptomatic diagnosis and carrier detection. How ever, in sporadic Cl livl cases in which the diagno sis is less certain, mutation detection remains inevitable*
